ILEVRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(9 years ago) | |
| US6403609 | HARROW EYE | Ophthalmic compositions containing galactomannan polymers and borate |
Jul, 2018
(5 years ago) | |
| US7947295 | HARROW EYE | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(a month from now) | |
| US9662398 | HARROW EYE | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(6 years from now) | |
| US8921337 | HARROW EYE | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(7 years from now) | |
Ilevro is owned by Harrow Eye.
Ilevro contains Nepafenac.
Ilevro has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ilevro are:
- US5475034
- US6403609
Ilevro was authorised for market use on 16 October, 2012.
Ilevro is available in suspension/drops;ophthalmic dosage forms.
Ilevro can be used as method of treating ocular inflammation.
The generics of Ilevro are possible to be released after 31 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage
ILEVRO family patents
